Press Release September 20, 2022

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

The Life Sciences team advised Redmile Group on leading the private placement purchase of 5,350,000 shares of Ventyx Biosciences, Inc.’s (Nasdaq: VTYX) common stock at an offering price of $33.00 per share. Gross proceeds of the private placement are expected to be approximately $176.6 million, before deducting placement agent fees and other expenses.

Redmile Group is a healthcare investment organization that does venture, growth and crossover investing across healthcare.

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders.

The Goodwin team was led by Maggie Wong and Della Fok.

For more details, read the press release and articles in BioSpace.